DDInter969 DDInter1491
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Budesonide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Budesonide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Calaspargase pegol {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Fluvastatin {u} may lead to a major life threatening interaction when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)